uniQure N.V. (QURE)
Nasdaq · Healthcare · Biotechnology
$22.80−2.81%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $1.6B
- 52-week range
- $8.73 – $71.50
- 52-week change
- −55.66%
- EPS (trailing)
- −$4.03
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Revenue
- $16.1M (−40.64%)
- Net income
- −$199M
- Operating margin
- −1151.4%
- Diluted EPS
- −$3.46
- Free cash flow
- −$178M
From the company’s annual report on SEC EDGAR.
About uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Headquarters: Amsterdam, Netherlands · 221 employees · uniqure.com